Verastem Oncology Announces Initial Results of RAMP 203 Trial of Avutometinib and LUMAKRAS™ (sotoras
Avutometinib + Sotorasib Combination Demonstrated Preliminary Efficacy with Confirmed Responses in both KRAS G12C Inhibitor Resistant and Naïve PatientsNo New Safety Signals Observed in Combination; Most Treatment-Related Adverse Events Mild to ModerateEnrollment of Patients Naïve to or Previously Treated with a KRA...
Source: pharmiweb.com